We have recently observed that patients with malignant mel-anoma on treatment with
ipilimumab can demonstrate leptomeningeal enhancement on brain MR imaging mimicking …

Until recently, dacarbazine (DTIC) was the only registered chemotherapeutic drug for
systemic treatment of metastatic melanoma. Patients with progressive disease during DTIC …

8523 Background: Ipilimumab (Ipi), a human monoclonal antibody that blocks CTLA-4, has
activity in advanced melanoma. We present results from a phase II trial (CA184-042) to …

Anecdotal cases of partial or complete responses have been reported after ipilimumab
therapy for stage IV melanoma with brain metastasis treated earlier by surgery or …

Ipilimumab is a monoclonal antibody that prolongs survival in patients with metastatic
melanoma. 1 It targets the coinhibitory receptor cytotoxic T-lymphocyte-associated antigen-4 …

MATERIALS AND METHODS In order to assess the efficacy and safety of ipilimumab in
patients with CNS metastases in melanoma, a multicentre retrospective study was carried …

V600E mutant melanoma. The surgical cavity and remaining metastasis were treated with
stereotactic radiosurgery (SRS), followed by four cycles of ipilimumab, a CTLA-4 inhibitor. In …

Background: Melanoma is among the top three cancers to present with brain metastasis.
The risk of brain metastases in advanced melanoma increases with disease duration …

Metastasis to the brain is a frequent event in patients with advanced melanoma. Despite
treatment with neurosurgery, pancranial irradiation and high-precision conformal …

Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by
activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have …